ClinicalTrials.gg
CompletedNCT01999686POSITIFUpdated May 28, 2019

PCOS Treatment Using DLBS3233, Metformin, and Combination of Both

A Phase 3 interventional study of DLBS3233 and Metformin XR in Polycystic Ovary Syndrome (PCOS) and Insulin Resistance, sponsored by Dexa Medica Group. Completed at 7 sites in Indonesia. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-05-28.

Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing metformin in Polycystic Ovary Syndrome — 9 open to participants now, 11 under way, 3 of them phase 3. Metformin · Polycystic Ovary Syndrome.

Enrollment
17th of 113
186 · median 75
Started
2014
with 5 others
Phase 3
18 of 114
3 open now
Registered
52nd of 114
by date

Among the 114 studies testing metformin in Polycystic Ovary Syndrome, this one is the 17th largest by enrollment of the 113 interventional ones that give a count, is one of 6 that started in 2014, is one of 18 in phase 3, and was the 52nd registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

9 of the 114 studies testing metformin in Polycystic Ovary Syndrome are open now, in 11 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies testing metformin in Polycystic Ovary Syndrome, or all of them as a file.
02

Study summary

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

Read the detailed description

There will be 3 groups of treatment (N = 186), each consist of 62 subjects, as the following:

  • Treatment I : DLBS3233 100 mg once daily
  • Treatment II : Metformin XR 750 mg twice daily
  • Treatment III : DLBS3233 100 mg once daily and Metformin XR 750 mg twice daily.

Laboratory examination to evaluate metabolic efficacy parameters will be performed at baseline, Month 3rd, and end of study (Month 6th).

Clinical and laboratory examination to evaluate the reproductive efficacy parameters using trans-vaginal USG and biomarkers (such as reproductive hormones) will be performed at baseline to the end of study.

Safety examination will be performed at baseline and end of study. Occurrence of adverse event will be observed along the study conduct.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)
  • Insulin Resistance

Keywords

  • Polycystic ovarium syndrome
  • DLBS3233
  • metformin
  • insulin resistance
  • Female
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written prior to participation in the study.
  2. Female subjects in reproductive age (i.e. 18-40 years) willing to conceive.
  3. Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the following (Rotterdam Criteria):

    • Hyperandrogenism (defined by elevated free testosterone concentration; or Ferriman-Gallwey Score of ≥ 8).
    • Ovarian dysfunction indicated by menstrual irregularity: oligomenorrhea (cycles of > 35 days), or amenorrhea (no menses in the last of 3 months) after negative screening pregnancy test.
    • Polycystic ovary as shown by ultrasonography (USG).
  4. Subject with insulin resistance defined by : HOMA-IR of > 2.00.
  5. Subject with (BMI) of 19-35 inclusive.
  6. Able to take oral medication.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women (urinary pregnancy test will be applied at screening).
  2. Based on previous or current medical (either laboratory or clinical) examination, subjects known to have any of the following conditions:

    • Cushing's syndrome, late onset of congenital adrenal hyperplasia, androgen-secreting tumors, uncontrolled thyroid disease, hyperprolactinemia.
  3. Known to have the following medical condition:

    • Diabetes mellitus,
    • Uncontrolled hypertension
    • Symptomatic cardiovascular diseases:
    • Acute or chronic infections at baseline.
    • Any known .
  4. History of gynecological surgery.
  5. Impaired renal function
  6. Impaired liver function
  7. Medically-assisted weight loss with medications or surgical procedures.
  8. Currently having laparoscopic ovarian diathermy (LOD).
  9. Currently under treatment with in vitro fertilization (IVF) techniques.
  10. Have been regularly taking any of the following medications, within ≤ 3 months prior to screening, such as:

    • Clomiphene citrate
    • Insulin sensitizers, i.e. metformin and thiazolidinediones
    • Aromatase inhibitors, such as: anastrozole, letrozole
    • Gonadotropins
    • Gonadotropin-releasing hormone agonists (GnRHa)
    • Oral pills (OCPs)
    • Antiandrogens, such as: spironolactone, cyproterone acetate (CPA), and flutamide
    • Any traditional or herbal medicines
  11. Participating in other clinical trial within 30 days prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Treatment I : DLBS3233

    DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months

    Drug: DLBS3233 · Drug: Placebo metformin

  • Active comparator
    Treatment II : Metformin

    Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months

    Drug: Metformin XR · Drug: Placebo DLBS3233

  • Experimental
    Treatment III : Combination DLBS3233 and Metformin

    DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.

    Drug: DLBS3233 · Drug: Metformin XR

Interventions

  • Also known as: Inlacin

  • Also known as: Glumin XR

  • DrugPlacebo metformin

    Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).

  • DrugPlacebo DLBS3233

    Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).

06

What researchers measure

Primary outcomes

  1. HOMA-IR reduction

    HOMA-IR reduction from baseline to Month 6th (end of study)

    Time frame: 6 months

Secondary outcomes

  1. Lipid profile improvement

    Lipid profile improvement (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides level) from baseline to Month 3rd and Month 6th (end of study)

    Time frame: 3 and 6 months

  2. Improvement of glucose tolerance

    Improvement of glucose tolerance (reduction of FPG and 2-hour PPPG) from baseline to Month 3rd and Month 6th (end of study)

    Time frame: 3 and 6 months

  3. Change of waist circumference

    1, 2, 3, 4, 5, and 6 months

    Time frame: 1, 2, 3, 4, 5, and 6 months

  4. Response rate: presence of ovulation

    Presence of ovulation will be evaluated using trans-vaginal USG to find dominant follicle(s), at the day/period of ovulation, starting from menstrual cycle of Month 3rd up to Month 6th. Measurement of progesterone level will be performed 7 days after the finding of dominant follicle on USG examination to confirm the presence of ovulation.

    Time frame: menstrual cycle of Month 3rd up to that of Month 6th

  5. Change of endometrium thickness

    Change of endometrium thickness will be measured by using trans-vaginal USG at basal condition and at the day/period of ovulation

    Time frame: 3 to 6 months

  6. Improvement of S/A ratio

    Improvement from baseline of the S/A ratio (defined as the ratio between stromal and total area of median ovarian section) will be measured using trans-vaginal USG (trans-longitudinal measurement) at Baseline, menstrual cycle of Month 3rd, and menstrual cycle of Month 6th at basal condition.

    Time frame: 3 to 6 months

  7. Improvement in Ferriman-Gallwey Score

    Improvement in Ferriman-Gallwey Score from baseline to Month 3rd and Month 6th (the end of study)

    Time frame: 3 and 6 months

  8. Reduction of free testosterone level

    Reduction of free testosterone level from baseline to Month 6th (end of study)

    Time frame: 6 months

  9. Change of luteinizing hormone (LH) level

    Change of luteinizing hormone (LH) level from baseline to Month 6th (end of study)

    Time frame: 6 months

  10. Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio

    Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio from baseline to Month 6th (end of study)

    Time frame: 6 months

  11. Liver function

    Liver function (levels of serum AST, ALT, alkaline phosphatase) will be measured at baseline and Month 6th (end of study)

    Time frame: 6 months

  12. Renal function

    Renal function (levels of serum creatinine, BUN) will be measured at baseline and Month 6th (end of study)

    Time frame: 6 months

  13. Number of adverse events and subjects with events

    Adverse events as well as number of events and subjects experiencing the events will be observed and evaluated throughout study period (6 months) and until all adverse events have been recovered or stabilized

    Time frame: During 6 months

07

Study locations

7 sites
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lambung Mangkurat, Ulin Banjarmasin Hospital
    Banjarmasin, Indonesia
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Udayana, Sanglah Hospital
    Denpasar, Indonesia
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Hasanuddin, Dr. Wahidin Sudirohusodo Hospital
    Makasar, Indonesia
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya, Dr. Saiful Anwar Hospital
    Malang, Indonesia
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Sam Ratulangi, Prof. Dr. Kandou Hospital
    Manado, Indonesia
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital
    Semarang, Indonesia
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Airlangga, Dr. Soetomo Hospital.
    Surabaya, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Feb 2019 and a completion of May 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2013
First posted
Dec 3, 2013
Start
Oct 2014
Primary completionActual
Feb 2019
CompletionActual
May 2019
Last update
May 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01999686
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Dec 3, 2013
Start date
Oct 2014
Primary completion
Feb 2019
Completion
May 2019
Last update
May 28, 2019

Study contacts

Soehartono Ds, Prof. dr., SpOG-K
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Airlangga, Dr. Soetomo Hospital, Surabaya, Indonesia.
Arsana Wiyasa IW, Dr. dr., SpOG-K
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya, Dr. Saiful Anwar Hospital, Malang, Indonesia.
Putu Doster Mahayasa, dr., SpOG-K
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Udayana, Sanglah Hospital, Denpasar, Indonesia.
Syarief Taufik, dr., SpOG-K
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia.
Nusratuddin Abdullah, Dr. dr., SpOG-K, MARS
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Hasanuddin, Dr. Wahidin Sudirohusodo Hospital, Makasar, Indonesia.
Iwan Darma Putra, dr., SpOG-K
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lambung Mangkurat, Ulin Banjarmasin Hospital, Banjarmasin, Indonesia.
Eddy Suparman, Prof. Dr. dr., SpOG-K
principal investigator · Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Sam Ratulangi, Prof. Dr. Kandou Hospital, Manado, Indonesia.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: DLBS3233 · Metformin

Start the discussion